Sellas presents preclinical data on SLS009 CDK9 inhibitor in pancreatic cancer organoid models at AACR conference
Sellas Life Sciences disclosed preclinical pancreatic cancer data for SLS009, a CDK9 inhibitor, from patient-derived organoid studies. Results are being presented at the AACR Conference on Pancreatic Cancer, running Sept. 25-28, 2026, in San Diego. SLS009 showed stronger single-agent anti-tumor activity than a RAS inhi